Product information and disease descriptionProduct descriptionProduct information
Product comparison
15 evidence topics · 15 sources
Semaglutide 2.4 mg subcutaneous: STEP 1 primary endpoint at week 68
“In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More participants in the semaglutide group than in the placebo group discontinued treatment owing to gastrointestinal events (59 [4.5%] vs. 5 [0.8%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 7.2 mg subcutaneous: STEP UP primary endpoint at week 72
“Participants were randomly assigned (5:1:1) to receive once-weekly subcutaneous semaglutide 7·2 mg, 2·4 mg, or placebo, with a lifestyle intervention, for 72 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean change in bodyweight was greater with semaglutide 7·2 mg versus 2·4 mg (-18·7% [SE 0·4] vs -15·6% [0·7]; estimated treatment difference [ETD] -3·1% [95% CI -4·7 to -1·6]; p<0·0001) and with semaglutide 7·2 mg versus placebo (-18·7% [0·4] vs -3·9% [0·6]; -14·8% [-16·2 to -13·4]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events were more common with semaglutide 7·2 mg (711 [70·8%] of 1004) versus 2·4 mg (123 [61·2%] of 201) or placebo (86 [42·8%] of 201), as was dysaesthesia (230 [22·9%], 12 [6·0%], and one [0·5%], respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liraglutide 3.0 mg subcutaneous: SCALE Obesity and Prediabetes coprimary endpoints at week 56
“We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide subcutaneous: SURMOUNT-1 primary endpoint at week 72
“In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide versus semaglutide subcutaneous: SURMOUNT-5 head-to-head primary endpoint at week 72
“In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retatrutide subcutaneous, investigational: TRIUMPH-1 percent change in body weight at week 80
“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 2339 participants underwent randomization. The mean percent change in body weight in the retatrutide groups was -17.6% (4-mg dose), -23.7% (9-mg dose), and -25.0% (12-mg dose) versus -3.9% in the placebo group (differences, -19.8 and -21.0 percentage points, respectively; P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cagrilintide-semaglutide subcutaneous, investigational: REDEFINE 1 coprimary endpoints at week 68
“A total of 3417 participants underwent randomization, with 2108 assigned to receive cagrilintide-semaglutide, 302 to receive semaglutide, 302 to receive cagrilintide, and 705 to receive placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate in severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 2.4 mg subcutaneous in type 2 diabetes: STEP 2 primary endpoint at week 68
“From June 4 to Nov 14, 2018, 1595 patients were screened, of whom 1210 were randomly assigned to semaglutide 2·4 mg (n=404), semaglutide 1·0 mg (n=403), or placebo (n=403) and included in the intention-to-treat analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated change in mean bodyweight from baseline to week 68 was -9·6% (SE 0·4) with semaglutide 2·4 mg vs -3·4% (0·4) with placebo. Estimated treatment difference for semaglutide 2·4 mg versus placebo was -6·2 percentage points (95% CI -7·3 to -5·2; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide subcutaneous in type 2 diabetes: SURMOUNT-2 primary endpoint at week 72
“Adults (aged ≥18 years) with a body-mass index (BMI) of 27 kg/m2 or higher and glycated haemoglobin (HbA1c) of 7-10% (53-86 mmol/mol) were randomly assigned (1:1:1), using a computer-generated random sequence via a validated interactive web-response system, to receive either once-weekly, subcutaneous tirzepatide (10 mg or 15 mg) or placebo for 72 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12·8% (SE 0·6) and -14·7% (0·5), respectively, and -3·2% (0·5) with placebo, resulting in estimated treatment differences versus placebo of -9·6% percentage points (95% CI -11·1 to -8·1) with tirzepatide 10 mg and -11·6% percentage points (-13·0 to -10·1) with tirzepatide 15 mg (all p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 2.4 mg subcutaneous: weight regain after treatment withdrawal in the STEP 1 extension
“From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One year after withdrawal of once‐weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two‐thirds of their prior weight loss, with similar changes in cardiometabolic variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide subcutaneous: SURMOUNT-4 randomized withdrawal from week 36 to week 88
“At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean percent weight change from week 36 to week 88 was −5.5% with tirzepatide vs 14.0% with placebo (difference, −19.4% [95% CI, −21.2% to −17.7%]; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide subcutaneous: SURMOUNT-MAINTAIN continued, reduced, or withdrawn dosing to week 112
“After completing the initial weight-loss period with once weekly subcutaneous tirzepatide at the MTD (10 mg or 15 mg), adults (aged ≥18 years) with a BMI of 30 kg/m2 and above or 27 kg/m2 and above with one or more weight-related comorbidity, and a history of at least one self-reported unsuccessful dietary effort to lose bodyweight were randomly assigned in a 3:3:2 ratio to continue tirzepatide MTD, reduce to tirzepatide 5 mg, or switch to placebo for an additional 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model-based estimate percent change in bodyweight from baseline to week 112 was -21·9% (95% CI -23·5 to -20·3) with MTD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“-16·6% (95% CI -18·0 to -15·1) with 5 mg tirzepatide (ETD -6·6 [95% CI -8·3 to -5·0]), versus -9·9% (95% CI -11·1 to -8·8) with placebo (p<0·0001 for all comparisons)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral semaglutide 25 mg: OASIS 4 primary endpoint at week 64
“The participants were randomly assigned in a 2:1 ratio to receive oral semaglutide (25 mg) or placebo once daily, plus lifestyle interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 205 participants were randomly assigned to receive oral semaglutide, and 102 to receive placebo. The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group (estimated difference, -11.4 percentage points; 95% confidence interval, -13.9 to -9.0; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral orforglipron: ATTAIN-1 primary endpoint at week 72
“In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 3127 patients underwent randomization. The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events resulted in treatment discontinuation in 5.3 to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral orforglipron: ATTAIN-MAINTAIN switch from injectable incretin therapy at week 52
“Here this double-blind, placebo-controlled trial randomized participants previously treated with tirzepatide (cohort 1: N = 205) or semaglutide (cohort 2: N = 171) during the SURMOUNT-5 study to orforglipron once daily or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohort 1 participants who achieved body weight plateau maintained a model-based estimate (MBE) of 74.7% (s.e.m. 4.05) of body weight reduction with orforglipron compared with an MBE of 49.2% (s.e.m. 3.92) with placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohort 2 participants who achieved body weight plateau maintained an MBE of 79.3% (s.e.m. 4.42) of body weight reduction with orforglipron compared with an MBE of 37.6% (s.e.m. 7.46) with placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trial limitations include the absence of a comparator arm involving continued use of injectable obesity-management medications and the trial’s 1-year duration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote